Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Accendra Health, Inc.NYSE: ACH
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 466.8% from a year ago
Cash & equivalents stood at $336.88M at the end of Q1 FY2026, up 466.8% from a year earlier and up 19.5% from the prior quarter. Over 3 fiscal years it compounded at +59.5% a year.
Context
- Cash & equivalents amounted to 13.9% of total assets at the end of Q1 FY2026, up 12.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +466.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 281.99M USD
- Year-over-year change
- +471.0%
- 4-year CAGR
- +50.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 281.99M | +471.0% |
| FY2024 | 2024-12-31 | 49.38M | -79.7% |
| FY2023 | 2023-12-31 | 243.04M | +249.9% |
| FY2022 | 2022-12-31 | 69.47M | +24.7% |
| FY2021 | 2021-12-31 | 55.71M | — |
Cash & Equivalents vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +466.8% is the highest of 11, against a peer median of -11.2%.
- Cash & equivalents amounts to 13.9% of total assets for ACH, versus a peer median of 46.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$364.68M CAD | +220.4% | -8.7% | 32.6% | |
| Mar 2026 | $336.88M USD | +466.8% | +59.5% | 13.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M USD | -6.1% | +89.8% | 60.8% |
| Mar 2026 | $123.65M USD | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $116.64M USD | -11.5% | +0.6% | 78.7% | |
| Mar 2026 | $84.96M USD | -21.9% | -20.8% | 77.4% | |
| Mar 2026 | $72.3M USD | -29.6% | -10.7% | 72.5% | |
| Apr 2026 | CA$36.51M CAD | +5.2% | +24.0% | 10.5% | |
| Mar 2026 | $30.56M USD | -59.7% | -21.8% | 12.3% | |
| Mar 2026 | $30.31M USD | -28.6% | -5.8% | 7.7% | |
| Mar 2026 | $28.66M USD | -5.6% | -23.9% | 14.4% | |
| Peer median (excluding ACH) | — | -11.2% | -7.3% | 46.7% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55.71M | 69.47M | 243.04M | 49.38M | 281.99M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 681.56M | 763.5M | 598.26M | 690.24M | 95.91M |
| Inventory | 1.5B | 1.33B | 1.11B | 1.13B | 74.44M |
| Other Current Assets | 88.56M | 128.64M | 150.89M | 149.52M | 95.54M |
| Total Current Assets | 2.32B | 2.3B | 2.1B | 2.02B | 547.87M |
| Property, Plant & Equipment (Net) | 511.24M | 858.93M | 840.51M | 864.97M | 365.26M |
| Goodwill | 390.19M | 1.64B | 1.64B | 1.33B | 1.23B |
| Intangible Assets | 243.75M | 483.74M | 361.84M | 296.73M | 136.47M |
| Long-term Investments | 16.32M | 15.46M | 8.45M | 6.11M | 1.34M |
| Tax Assets | 0 | 0 | (8.45M) | 0 | 0 |
| Other Non-current Assets | 53.25M | 96.26M | 149.35M | 134.05M | 172.69M |
| Total Non-current Assets | 1.21B | 3.09B | 2.99B | 2.63B | 1.9B |
| Total Assets | 3.54B | 5.39B | 5.09B | 4.66B | 2.45B |
| Account Payables | 1B | 1.15B | 1.17B | 1.25B | 363.57M |
| Short-term Debt | 43.85M | 15.38M | 204.08M | 40M | 293.27M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 116.4M | 0 | 0 |
| Other Current Liabilities | 182.35M | 227.44M | 191.66M | 425.54M | 220.81M |
| Total Current Liabilities | 1.34B | 1.57B | 1.89B | 1.87B | 947.08M |
| Long-term Debt | 936.23M | 2.47B | 1.88B | 1.8B | 1.87B |
| Deferred Tax Liabilities | 35.31M | 60.83M | 41.65M | 22.46M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 108.94M | 114.94M | 122.59M | 100.13M | 25.15M |
| Total Non-current Liabilities | 1.25B | 2.87B | 2.28B | 2.22B | 1.97B |
| Total Liabilities | 2.6B | 4.44B | 4.17B | 4.09B | 2.91B |
| Common Stock | 150.87M | 152.56M | 153.09M | 154.4M | 152.78M |
| Retained Earnings | 387.62M | 410.01M | 368.71M | 6.02M | (1.08B) |
| Accumulated OCI | (40.59M) | (35.85M) | (31.82M) | (49.34M) | (885K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 938.5M | 945.6M | 924.17M | 565.23M | (460.98M) |
| Total Debt | 1.15B | 2.79B | 2.41B | 2.14B | 2.23B |
| Net Debt | 1.1B | 2.72B | 2.16B | 2.09B | 1.95B |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.